{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim GB"],"funding":["NIAID NIH HHS","NCI NIH HHS"],"pagination":["eabo6135"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10130759"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(660)"],"pubmed_abstract":["T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed on healthy tissue in combination with high-affinity TCRs that when introduced into T cells can redirect T cells to eliminate tumor but not healthy tissue is a key requirement for safe and efficacious TCR-based therapies. To discover promising shared tumor antigens that could be targeted via TCR-based adoptive T cell therapy, we employed population-scale immunopeptidomics using quantitative mass spectrometry across ~1500 tumor and normal tissue samples. We identified an HLA-A*02:01-restricted pan-cancer epitope within the collagen type VI α-3 (<i"],"journal":["Science translational medicine"],"pubmed_title":["Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy."],"pmcid":["PMC10130759"],"funding_grant_id":["P30 CA016520","T32 CA009140","P30 AI045008"],"pubmed_authors":["Tsou CC","Srivatsa S","Boesmueller H","Hoffgaard F","Goldfinger V","Reinhardt C","Hofmann M","Maldini CR","Jiang S","Alten L","Jaworski M","Unverdorben F","Baues M","Treiber T","Singh H","Fritsche J","Alpert A","Fuhrmann D","Kim GB","Weinschenk T","Schoor O","Kowalewski DJ","Missel S","Hutt M","Roemer M","Wagner C","Bunk S","Song C","Kong H","Glover J","Schraeder C","Mahr A","Tosh K","Walter S","Ott M","Maurer D","Dopkin D","Riley JL","Schuster H","Zhang CX","Schimmack G","Lau C"],"additional_accession":[]},"is_claimable":false,"name":"Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.","description":"T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed on healthy tissue in combination with high-affinity TCRs that when introduced into T cells can redirect T cells to eliminate tumor but not healthy tissue is a key requirement for safe and efficacious TCR-based therapies. To discover promising shared tumor antigens that could be targeted via TCR-based adoptive T cell therapy, we employed population-scale immunopeptidomics using quantitative mass spectrometry across ~1500 tumor and normal tissue samples. We identified an HLA-A*02:01-restricted pan-cancer epitope within the collagen type VI α-3 (<i","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-29T06:37:05.515Z","creation":"2025-02-19T02:03:56.611Z"},"accession":"S-EPMC10130759","cross_references":{"pubmed":["36044599"],"doi":["10.1126/scitranslmed.abo6135"]}}